Overview

Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

Status:
Completed

Trial end date:
2008-06-01

Target enrollment:

Participant gender:

Summary

Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%

Phase:

Phase 2

Details

Lead Sponsor:

Galderma
Galderma R&D

Treatments:

Brimonidine Tartrate
Ophthalmic Solutions
Pharmaceutical Solutions